Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019 Jun; 54(6):2189-2199.